Introduction {#s01}
============

In skeletal muscle, bidirectional signaling occurs between the dihydropyridine receptor, an L-type Ca^2+^ channel that contains Ca~V~1.1 (α~1S~) as its principle subunit and is located in the plasma membrane, and the type 1 ryanodine receptor (RyR1), which is a Ca^2+^ release channel located in the SR. In response to depolarization of the plasma membrane, Ca~V~1.1 transmits an "orthograde" signal that activates RyR1 to release Ca^2+^ ([@bib27]; [@bib1]). In addition, a "retrograde" interaction occurs whereby the association with RyR1 increases the magnitude of the voltage-gated Ca^2+^ current carried via Ca~V~1.1 ([@bib19]). The orthograde signal does not require the influx of extracellular Ca^2+^ via the L-type current of Ca~V~1.1 ([@bib3]), and the retrograde signal does not depend on the Ca^2+^ flux via RyR1 ([@bib4]), which has led to the notion that bidirectional signaling involves conformational coupling between Ca~V~1.1 and RyR1.

An approach that has been extensively used in the attempt to identify regions of Ca~V~1.1 important for conformational coupling with RyR1 has been to create chimeras between Ca~V~1.1, which does support bidirectional signaling, and Ca~V~ isoforms that do not support such signaling, followed by expression in dysgenic (Ca~V~1.1 null) myotubes to assess function. This approach revealed that full bidirectional signaling depends on the presence of a critical domain of ∼46 amino acids (residues 720--764/5) within the cytoplasmic II--III loop of Ca~V~1.1 ([@bib20]; [@bib12]; [@bib28]). However, neither the reason why these residues are important for controlling activation of RyR1 nor the identity of proteins they directly contact has been established to date.

One important reason why it has been difficult to elucidate the role of the critical domain in bidirectional signaling between Ca~V~1.1 and RyR1 is that this signaling requires the presence of additional proteins. One of these is the β~1a~ auxiliary subunit of Ca~V~1.1. As for other Ca~V~β and high-voltage--activated Ca^2+^ channel isoforms, β~1a~ facilitates membrane trafficking of Ca~V~1.1 ([@bib6]; [@bib25]). Additionally, the ability of Ca~V~1.1 to transmit the orthograde excitation--contraction (EC) coupling signal to RyR1 depends on the presence of specific sequences within β~1a~ ([@bib6]; [@bib25]). A second, recently discovered protein of similar importance is Stac3, one of three isoforms of Stac protein; Stac3 is highly expressed in skeletal muscle, whereas Stac1 and Stac2 are predominantly expressed in nervous tissue ([@bib21]). Membrane expression is reduced ([@bib24]) and EC coupling ablated in mouse and fish muscle null for Stac3 ([@bib13]; [@bib21]). Membrane expression, but not EC coupling, is largely restored in mouse muscle ([@bib24]) by a Stac3 construct bearing a point mutation that is responsible for a severe, recessively inherited myopathy ([@bib13]). Thus, Stac3 appears to play a crucial role in EC coupling, but just as for the critical domain of Ca~V~1.1, the molecular interactions underlying this role have not been elucidated.

Our previous work indicated that Stac3 binds directly to Ca~V~1.1 ([@bib23]) but did not identify the regions of both proteins responsible for their binding to one another. All three Stac isoforms contain a PKC C1 domain and SH3 domains, although sequence of each of these domains varies somewhat between isoforms. The regions linking these conserved domains vary between isoforms. [@bib7] analyzed the ability of Stac protein constructs to cluster at plasma membrane--SR junctions in dysgenic myotubes. Specifically, they compared clustering abilities of Stac3 with those of Stac1 and Stac2, as well as the clustering abilities of Stac3/Stac2 chimeras and Stac3 bearing one or more amino acid substitutions. They concluded that the PKC C1 domain of Stac3 is important for its binding to Ca~V~1.1.

Here, we used a different set of approaches. One of these was to compare the abilities of Stac1, Stac2, and Stac3 to support membrane expression of Ca~V~1.1 in tsA201 cells and restore EC coupling in Stac3-null myotubes. Another was to assess interactions between the fluorescently tagged Stac proteins and Ca~V~ constructs after their coexpression in tsA201 cells, because interactions observed in these cells are likely to be directly between the expressed proteins. We used both the full-length Ca~V~ constructs that had been previously tested for function in dysgenic myotubes and isolated Ca~V~1.1 cytoplasmic domains coupled to a sequence (the I--II loop of Ca~V~1.2) that had been shown to traffic to the surface membrane of tsA201 cells ([@bib26]; [@bib14]). Based on colocalization as an indicator of interaction, we concluded that all three Stac isoforms bound to the Ca~V~1.1 II--III loop. All three isoforms also interacted, to varying extents, with Ca~V~1.1 in tsA201 cells and Stac3-null myotubes. Moreover, subdivision of the II--III loop indicated that the domain previously shown to be functionally critical for bidirectional signaling (residues 720--764/5) was also important for the binding of Stac3. As another approach, we expressed fluorescently tagged Stac proteins in dysgenic myotubes together with fluorescently tagged, full-length Ca~V~ constructs. This approach revealed that, as in tsA201 cells, Stac3 binding in muscle cells depended on sequence contained within the critical domain of the II--III loop. Thus, our results on Stac3 interactions suggest a previously unknown role for the critical domain, which is that it is required for the binding of Stac3, which in turn is required for the ability of Ca~V~1.1 to transmit the EC coupling signal to RyR1.

Materials and methods {#s02}
=====================

Molecular biology {#s03}
-----------------

The construction of the expression plasmids for GFP-Ca~V~1.1, YFP-Ca~V~1.1, GFP-SkLC, GFP-SkLCS~46~, GFP-SkLCS~18~, GFP-SkLM, GFP-SkLMS~45~, unlabeled β~1a~, Stac2-YFP, Stac3-YFP, unlabeled Stac2, and unlabeled Stac3 was described previously ([@bib11], [@bib12]; [@bib28]; [@bib22]; [@bib23]). The expression vectors for YFP-Ca~V~1.1 ([@bib22]) and YFP-Ca~V~1.2 ([@bib23]) were used as templates to amplify the sequence of defined, cytoplasmic domains of the channels via standard PCR. Subsequent digestion of the PCR products at restriction sites introduced at both ends during amplification allowed for later ligation into the multiple cloning site of pEGFP-C1 (Clontech). The following is a list of the constructs used in this study, of their forward (fw) and reverse (rev) primers with the respective enzymes used for restriction, followed by the range of encoded rabbit Ca~V~1.1 (GenBank: [X05921](X05921)[.1](.1)), Ca~V~1.2 (GenBank: [X15539](X15539)[.1](.1)), and *Musca domestica* Ca~V~1.1 ([@bib28]) amino acid residues: GFP-N-term(Ca~V~1.1): fw 5′-GAACCGGTCATGGAGCCATCCTCACCCCAG-3′, AgeI, rev 5′-GTACCGGTTTCCATTCCACGATGCTGATG-3′, AgeI, residues 1--52; GFP-I--II(Ca~V~1.1): fw 5′-GGGGTACCGGGGAATTCACCAAGGAGCG-3′, KpnI, rev 5′-CCCCCGGGCTCGACTTCACCAGGTCATGGC-3′, XmaI, residues 335--431; GFP-II--III(Ca~V~1.1): fw 5′-GATTGTCGACAACCTGGCCGAGGCGGAG-3′, SalI, rev 5′-GTGGATCCAGGTGGCGTTGACGATGCGG-3′, BamHI, residues 660--800; GFP-662-730(Ca~V~1.1): fw 5′-GCAGTCGACAACCTGGCCGAGGCGGAGAGC-3′, SalI, rev 5′-GGCGGATCCCTAGTTGACGTTAGATTCGAAC-3′, BamHI, residues 662--730; GFP-697-765(Ca~V~1.1): fw 5′-GCAGTCGACGAGAAGTCTGTGATGGCCAAG-3′, SalI, rev 5′-GGCGGATCCCTACTGCAGCTCGGCCAGCGGGC-3′, BamHI, residues 697--765; GFP-731-799(Ca~V~1.1): fw 5′-GCAGTCGACGAGGTGAAGGACCCCTACCCTTC-3′, SalI, rev 5′-GGCGGATCCCTAGGTGGCGTTGACGATGCGG-3′, BamHI, residues 731--799; GFP-III--IV(Ca~V~1.1): fw 5′-CAGGTACCGTCACCTTCCAGGAGCAG-3′, KpnI, rev 5′-GTCCCGGGAGGAGGTGACGACGTACC-3′, XmaI, residues 1,066--1,118; GFP-C-term(Ca~V~1.1): fw 5′-GCAGTCGACTTTGACTACCTGACACGCGAC-3′, SalI, rev 5′-GGCGGTACCCTACTGGTCAAGGCTGCCCAGG-3′, KpnI, residues 1,384--1,855; GFP-I--II(Ca~V~1.2): fw 5′-GCAGTCGACGGAGAGTTTTCCAAAGAGAGG-3′, SalI, rev 5′-GGCGGATCCCTAGTTCGACTTGACCGCTGCG-3′, BamHI, residues 436--554; GFP-II--III(Ca~V~1.2), GFP-II--III(SkLCS~46~), GFP-II--III(SkLCS~18~): fw 5′-GCAGTCGACAACCTGGCTGATGCTGAGAGC-3′, SalI, rev 5′-GGCGGATCCCTACGTGTCGTTGACGATACGG-3′, BamHI, residues 784--930; GFP-II--III(SkLM), GFP-II--III(SkLMS~45~): fw 5′-GCAGTCGACGATAACTTAGCAGACGCTG-3′, SalI, rev 5′-GGCGGATCCCTAGGTGGCGTTGACGATGCGG-3′, BamHI, residues 665--790.

To add the Ca~V~1.2 I--II-loop sequence to these GFP-labeled intracellular Ca~V~ domains, PCR with the primers fw 5′-GCCTCGAGGAGAGTTTTCCAAAGAGAGG-3′ and rev 5′-GCAAGCTTCCTTGACCGCTGCGCGGCACTTTC-3′ was used to introduce XhoI and HindIII sites flanking the I--II loop (residues 436--552) of Ca~V~1.2 from which the I--II loop--containing XhoI--HindIII fragment was inserted into the plasmids of GFP-labeled cytoplasmic domains of Ca~V~1.1 and the II--III loops of SkLC, SkLCS~46~, SkLCS~18~, SkLM, or SkLMS~45~.

PCR with the primers fw 5′-CTGAGGTACCAACCATGATTCCTCCAAGTGGCGCC-3′ and rev 5′-GTGGTACCAACACGTCTACCAGTACATCC-3′ or rev 5′-GTGGTACCTACACGTCTACCAGTACATCC-3′ was used to introduce KpnI sites, or KpnI sites and a stop codon, flanking the coding sequence for Stac1 (gene ID 20840; Cedarlane Laboratories), from which the KpnI--KpnI fragments were inserted into EYFP-N1(Clontech) to create Stac1-YFP or into pECFP-N1 (Clontech). Afterward, the latter construct was digested with NdeI and BamHI, and the fragment containing the Stac1 sequence was then ligated to the 3,575-bp fragment of pEYFP-C1 (Clontech) that had been digested with the same enzymes to produce the expression vector for unlabeled Stac1.

PCR with the primers fw 5′-GCTGGTTTAGTGAACCGTCAGATCCGCTAGC-3′ and rev 5′-GTGCGGCCGCTAATTAAGTTTGTGCCCCAGTTTGC-3′ was used to amplify the coding sequence for tagRFP from tagRFP-C1 (Clontech) and to introduce AgeI and NotI sites flanking tagRFP and a stop codon. The AgeI--NotI fragment was then inserted into the vector encoding for EYFP-N1 (Clontech) to create tagRFP-N1. To create Stac3-RFP, the tagRFP-containing fragments from tagRFP-N1 was inserted into Stac3-YFP ([@bib23]), using the restriction enzymes BamHI and NotI. To create Stac1- or Stac2-RFP, the Stac1- or Stac2-containing fragments from Stac1-YFP or Stac2-YFP ([@bib23]) replaced Stac3 in Stac3-RFP, using the restriction enzymes NdeI and BamHI.

PCR with the fw primer 5′-GCAGAATTCATGCACAAGTTCAAAGATCAC-3′, 5′-GCAGAATTCATGTTCCGTCGGGCCTATAGC-3′, or 5′-GCAGAATTCATGGGAGAACGTGTGCACCGC-3′ and rev primer 5′-GGCGGATCCGCAATCTCCTCCAGGAAGTCG-3′ was used to introduce EcoRI and BamHI sites flanking the coding sequence for Stac3 fragments from which the EcoRI-BamHI fragment was inserted into tagRFP-N1 to create Stac3(Δ87)-RFP, Stac3(Δ146)-RFP, and Stac3(Δ302)-RFP, respectively. To produce unlabeled Stac3(Δ146) for electrophysiological experiments, PCR with the primers fw 5′-GCAGAATTCATGTTCCGTCGGGCCTATAGC-3′ and rev 5′-GTGGTACCTAAATCTCCTCCAGGAAGTCG-3′ was used to introduce EcoRI and KpnI sites and a stop codon flanking the coding sequence for Stac3, from which the EcoRI-KpnI fragment was inserted into the vector of unlabeled Stac1 (see above) that had been digested with the same enzymes.

The α~2~-δ~1~ subunit was kindly provided by William A. Sather (University of Colorado, Denver, CO). All constructs were verified by enzyme digestion and sequence analysis.

tsA201 cell culture and expression of cDNA {#s04}
------------------------------------------

tsA201 cells were propagated in high-glucose DMEM supplemented with 10% (vol/vol) FBS and 2 mM glutamine in a humidified incubator with 5% (vol/vol) CO~2~. Cells were plated at a density of 2 × 10^5^ cells in 35-mm dishes and transfected 24 h later with jetPRIME (Polyplus-transfection Inc.) with various cDNA combinations of GFP-Ca~V~1.1, YFP-Ca~V~1.1 (1 µg/dish), β~1a~, α~2~-δ~1~, GFP (and Ca~V~1.2 I--II loop)--labeled intracellular channel regions, and unlabeled or RFP-labeled Stac protein isoforms or fragments (0.5 µg/dish). 4 h after transfection, cells were removed from the dish, using Trypsin EDTA (Mediatech), split 1:2 into fresh medium, and replated into 35-mm culture dishes with glass-coverslip bottoms (MatTek) for imaging or at ∼1 × 10^4^ cells per 35-mm culture dish to obtain isolated cells for electrophysiological recording. Approximately 48 h after transfection, positively transfected cells were identified by the pattern of yellow or green (and red) fluorescence and were used for electrophysiology or imaging.

Primary skeletal muscle cell culture and cDNA microinjection {#s05}
------------------------------------------------------------

All procedures involving mice were approved by the University of Colorado Denver-Anschutz Medical Campus Institutional Animal Care and Use Committee. Myoblasts from newborn dysgenic mice homozygous for absence of Ca~V~1.1 (a total of four independent culture preparations; [@bib27]) or embryonic day 18.5 fetuses, homozygous or heterozygous for the absence of Stac3 (a total of two independent culture preparations each), were prepared as described before ([@bib5]; [@bib21]). Myoblasts were plated into 35-mm culture dishes with ECL-coated glass-coverslip bottoms. Cultures were grown in a humidified 37°C incubator with 5% (vol/vol) CO~2~ in high-glucose DMEM (Mediatech) supplemented with 10% (vol/vol) FBS and 10% (vol/vol) horse serum (both from HyClone Laboratories). After 4--5 d, this medium was replaced with differentiation medium (DMEM supplemented with 2% \[vol/vol\] horse serum). 2--4 d after the shift to differentiation medium, single nuclei were microinjected with plasmid cDNA (150 ng/µl for GFP-labeled full-length channels, 20 ng/µl for Stac constructs, and/or 5 ng/µl for BFP \[pmTagBFP2-N1; Addgene\] in water). 48 h after injection, expressing cells were identified on the basis of GFP and tagRFP, BFP, or YFP fluorescence.

Confocal microscopy, photobleaching, and colocalization quantification {#s06}
----------------------------------------------------------------------

Myotubes or tsA201 cells were superfused with rodent Ringer's solution (146 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, and 10 mM HEPES, pH 7.4, with NaOH) and examined using a Zeiss LSM 710 confocal microscope. Excitation and emission (nanometers) for the fluorescent proteins were GFP (ex: 488, em: 493--590), YFP (ex: 514, em: 530--565), and tagRFP (ex: 543, em: 582--754). Relative to full power output, the excitation was attenuated to ∼1% (488 nm), ∼2% (514 nm), and ∼2--4% (543 nm). Images were obtained with a 40× (1.3 numerical aperture) oil-immersion objective as a single, midlevel optical slice that was halfway between the substrate and upper cell surface for tsA201 cells and near the substrate for myotubes. For comparing the distribution of labeled Stac and Ca~V~ constructs, myotubes were selected on the basis of a punctate distribution of the labeled Ca~V~ construct. tsA201 cells were selected for subsequent analysis on the basis of isolation from surrounding cells and an initial mid-level optical scan displaying (1) close association of the tagged Ca~V~ construct with the perimeter of the cell and (2) high expression of the tagged Stac construct as judged by a uniformly strong fluorescence throughout the entire optical section. The mobile fraction of the tagged Stac was then photobleached by repeatedly scanning for 15--45 s with nonattenuated excitation within a region of interest that was designated to avoid the cell surface. A second midlevel scan acquired afterward was used to assess colocalization.

To quantify colocalization, the fluorescence intensity of Stac-RFP fluorescence was compared with that of GFP-labeled Ca~V~ constructs ZEN 2.3 SP1 (Black) software (Carl Zeiss Microscopy). After subtraction of background intensity measured in a cell-free region, a digital mask (compare Fig. 6 of [@bib22]) was produced by application of an adjustable threshold to the GFP image such that all pixel values at or below the threshold were excluded form analysis, and all values above the threshold (i.e., the majority of the surface-associated fluorescence in tsA201 cells or the fluorescent puncta in myotubes) were included. For those Ca~V~ constructs that produced aggregates in the interior of tsA201 cells (see [Fig. 4](#fig4){ref-type="fig"}), the mask was created only from the regions of the cell in which the interior aggregates were absent. Pearson's coefficients for colocalization of green and red fluorescence within the digital mask were calculated as$$PCC = \frac{\sum\limits_{i = 1}^{n}{\left( {F_{EGFP,i} - \overline{F_{EGFP}}} \right) \cdot \left( {F_{RFP,i} - \overline{F_{RFP}}} \right)}}{\sqrt{{\sum\limits_{i = 1}^{n}\left( {F_{EGFP,i} - \overline{F_{EGFP}}} \right)}^{2} \cdot {\sum\limits_{i = 1}^{n}\left( {F_{RFP,i} - \overline{F_{RFP}}} \right)}^{2}}},$$where *F~EGFP,i~* and *F~RFP,i~* are the background-corrected fluorescence intensities (*F*) measured for EGFP-labeled channel (fragments) with tagRFP-labeled Stac constructs at the *i*^th^ pixel, respectively. *n* is the total pixel number of the generated mask, and $\overline{F_{EGFP}}$ and $\overline{F_{RFP}}$ are the mean *F* values for that mask.

To measure the dissociation of Stac3 from Ca~V~1.1, dysgenic myotubes injected with cDNAs for GFP-Ca~V~1.1 and Stac3-RFP were washed 48 h after injection with "internal solution" consisting of (mM) 140 Cs-aspartate, 10 Cs~2~-EGTA, 5 MgCl~2~, and 10 HEPES, pH 7.4, with CsOH. The myotubes were then permeabilized with saponin (12 µg/ml in internal solution) for 30 s, washed twice with internal solution, and thereafter imaged immediately (0 min) and 5, 15, 30, 45, and 60 min later. The ratio of red to green fluorescence intensity (I~R~/I~G~) was calculated at these time points after creation of a digital mask as described above.

Measurement of L-type Ca^2+^ currents {#s07}
-------------------------------------

All experiments were performed at room temperature (∼25°C). Pipettes (∼2.0 MΩ) were filled with internal solution (see above). The external solution contained (in millimolar) 145 tetraethylammonium-Cl, 10 CaCl~2~, and 10 HEPES, pH 7.4, with tetraethylammonium-OH. L-type currents were measured in response to test pulses applied directly from the holding potential (−80 mV). Electronic compensation was used to reduce the effective series resistance to \<5 MΩ (time constant \<400 µs). Linear components of leak and capacitive current were corrected with −P/4 online subtraction protocols. Filtering was at 2--5 kHz and digitization was at 10 kHz. Cell capacitance was determined by integration of a transient elicited by stepping from the holding potential to −70 mV using Clampex 8.2 (Molecular Devices) and was used to normalize ionic currents (picoamperes per picofarad). Peak I--V curves were fitted according to:$$I = {{G_{\max}\left( {V - V_{rev}} \right)}/\left\{ {1 + \exp\left\lbrack {{- \left( {V - V_{1/2}} \right)}/k_{G}} \right\rbrack} \right\}},$$where *I* is the peak current for the test potential *V*, *V*~rev~ is the reversal potential, *G*~max~ is the maximum Ca^2+^ channel conductance, *V*~1/2~ is the half-maximal activation potential and *k*~G~ is the slope factor.

Measurement of intracellular Ca^2+^ transients {#s08}
----------------------------------------------

Changes in intracellular Ca^2+^ were recorded with Fluo-3 (Molecular Probes) in the whole-cell patch-clamp configuration (see above). The salt form of the dye was added to the standard internal solution for a final concentration of 200 nM. After entry into the whole-cell configuration, a waiting period of \>5 min was used to allow the dye to diffuse into the cell interior. A Zeiss LSM 710 was used to excite the dye (488 nm) and measure fluorescence emission (519--585 nm) in the voltage-clamped myotube during 200-ms test pulses. Fluorescence data are expressed as Δ*F/F*, where Δ*F* represents the peak change in fluorescence from baseline during the test pulse and *F* is the fluorescence immediately before the test pulse minus the mean background (non--Fluo-3) fluorescence. The fluorescence change (Δ*F*/*F*) for each test potential (V) was fitted according to$$\left( {{\Delta F}/F} \right) = {\left( {{\Delta F}/F} \right)_{max}/\left\{ {1 + \exp\left\lbrack {\left( {V_{F} - V} \right)/k_{F}} \right\rbrack} \right\}},$$where (Δ*F*/*F*)~max~ is the maximal fluorescence change, *V*~F~ is the potential causing half the maximal change in fluorescence, and *k*~F~ is a slope parameter.

Analysis {#s09}
--------

The software program SigmaPlot (version 11.0; SSPS) was used for statistical analysis, curve fitting, and preparation of figures. All data are presented as mean ± SEM.

Online supplemental material {#s10}
----------------------------

Fig. S1 shows Stac proteins do not associate intrinsically with the surface of tsA201 cells. Fig. S2 shows Stac proteins do not interact with the GFP-tagged I--II loop of Ca~V~1.2. Fig. S3 shows Stac1 associates specifically with the Ca~V~1.1 II--III loop in tsA201 cells. Fig. S4 shows Stac2 associates specifically with the Ca~V~1.1 II--III loop in tsA201 cells.

Results {#s11}
=======

Our initial strategy in this work was to determine whether differences between the predominantly neuronal Stac isoforms (Stac1 and Stac2) and the muscle isoform (Stac3) could be exploited as a means of identifying domains of Stac3 important for its interactions with Ca~V~1.1. Previously, we had found that Ca^2+^ currents were absent in tsA201 cells transfected only with Ca~V~1.1, β~1a~ and α~2~-δ~1~. However, in cells transfected with Ca~V~1.1, β~1a~ and α~2~-δ~1~ plus Stac3, Stac3, and Ca~V~1.1 were colocalized at the cell surface and robust Ca^2+^ currents were present ([@bib23]). Here, we tested the extent to which Stac1 and Stac2 could substitute for Stac3 in tsA201 cells ([Fig. 1](#fig1){ref-type="fig"}). To assess association at the surface, we used fluorescently tagged constructs of Ca~V~1.1 and Stac and applied strong illumination within the cellular interior to selectively bleach the mobile fraction of the labeled Stac construct. As shown previously for Stac3 ([@bib23]), no surface associated fluorescence was observed after application of this procedure to cells transfected only with labeled Stac1 or Stac2 (Fig. S1). However, fluorescently tagged Stac1 and Stac2 both remained associated with the surface when Ca~V~1.1 was also present ([Fig. 1 A](#fig1){ref-type="fig"}). Additionally, both Stac1 and Stac2 were able to support functional expression of Ca~V~1.1, although to a lesser extent than Stac3 ([Fig. 1, B and C](#fig1){ref-type="fig"}). Stac1 and Stac2 also appeared to function as partial substitutes for Stac3 in muscle cells null for endogenous Stac3. Thus, Stac1 and Stac2 displayed a punctate distribution when expressed in Stac3-null myotubes, which was similar to that of Stac3 ([Fig. 2 A](#fig2){ref-type="fig"}) and is consistent with binding to Ca~V~1.1 at plasma membrane junctions with the SR ([@bib23]). Moreover, Stac1 and Stac2 restored depolarization-evoked Ca^2+^ release in Stac-null myotubes to a level ∼40% of that restored by expression of Stac3 ([Fig. 2 B](#fig2){ref-type="fig"}).

![**All three Stac isoforms interact with full-length Ca~V~1.1 and promote its functional expression in tsA201 cells. (A)** Representative images of tsA201 cells cotransfected with GFP-Ca~V~1.1, β~1a~, α~2~-δ~1~, and either Stac1-RFP (top), Stac2-RFP (middle), or Stac3-RFP (bottom). Here, and in subsequent figures, images were obtained after red fluorescence was bleached within the indicated regions of interest. Bars, 5 µm. **(B and C)** Comparison of representative peak Ca^2+^ currents (B; V~test~ = +40 mV) and mean peak I--V relationships (C; mean ± SEM) in tsA201 cells cotransfected with YFP-Ca~V~1.1, β~1a~ and α~2~-δ~1~ either without Stac (green) or with Stac1 (red), Stac2 (blue), or Stac3 (black). Calibrations: 3 pA/pF (vertical), 50 ms (horizontal). The Ca^2+^ currents in B and peak I--V relationships in C obtained with Stac3, or without any Stac protein, are replotted from [@bib23].](JGP_201711917_Fig1){#fig1}

![**Expression of Stac1 or Stac2 in Stac3-null myotubes restores EC coupling Ca^2+^ release, although to a lesser extent than Stac3. (A)** Confocal scans near the surface reveal that after expression in Stac3-null myotubes, Stac1-YFP (left), Stac2-YFP (middle), and Stac3-YFP (right) were similarly distributed in a punctate fashion, consistent with targeting to plasma membrane junctions with the SR. Bar, 5 µm. **(B and C)** Representative Ca^2+^ transients measured with Fluo-3 (B) and peak fluorescence change (C; Δ*F*/*F*, mean ± SEM) as a function of test potential for myotubes from mice heterozygous for Stac3 KO (orange), null for Stac3 (green), or null for Stac3 and transfected with Stac3 (black), Stac1 (red), or Stac2 (blue). Test depolarizations were 200 ms in duration and applied from a −80 mV holding potential. In B, test potentials were −40, −20, 0, and +20 mV and the calibrations represent 1 Δ*F*/*F* (vertical) and 5 s (horizontal). The Stac constructs were unlabeled, and transfected cells were identified on the basis of cotransfected blue fluorescent protein (BFP). The Ca^2+^ transients and Δ*F*/*F* data for myotubes from mice heterozygous or homozygous for Stac3 KO, and for Stac3 KO myotubes transfected with Stac3, are replotted from [@bib24].](JGP_201711917_Fig2){#fig2}

Based on the results above, we next investigated whether the three Stac isoforms differed in their binding to one or more of the cytoplasmic domains of Ca~V~1.1 (illustrated schematically in [Fig. 3 A](#fig3){ref-type="fig"}, dashed box). Expressed in tsA201 cells, the Ca~V~1.1 II--III loop accumulated in bands around the nucleus, whereas the other cytoplasmic domains were diffusely present in the cytoplasm and, to some extent, diffusely distributed within the nucleus and also in small aggregates ([Fig. 3 A](#fig3){ref-type="fig"}). In the case of the I--II loop, a weak association with the surface could be observed after extensive bleaching of the mobile fraction within the cell interior (not depicted). However, to obtain a subcellular distribution more favorable for comparing interactions with Stac proteins, we linked the Ca~V~1.1 cytoplasmic domains to the I--II loop of Ca~V~1.2, which had been shown to provide a higher signal to noise ratio (surface vs. interior) in tsA201 cells ([@bib14]). As expected, we found that the GFP-tagged Ca~V~1.2 I--II loop strongly associated with the cell surface ([Fig. 3 B](#fig3){ref-type="fig"}, dashed box), and this was also the case after its linkage to the Ca~V~1.1 cytoplasmic domains ([Fig. 3 B](#fig3){ref-type="fig"}). Thus, fusions to the targeting sequence (GFP-tagged Ca~V~1.2 I--II loop) were used for all subsequent experiments on Ca~V~ cytoplasmic domains in tsA201 cells. In control experiments, comparison of pre and postbleach images (Fig. S2) demonstrated that none of the three Stac isoforms bound to the surface-targeting construct, GFP-I--II(Ca~V~1.2).

![**After linking to the I--II loop of Ca~V~1.2, the cytoplasmic domains of Ca~V~1.1 localize at the surface of tsA201 cells. (A)** Representative subcellular distributions in tsA201 cells of GFP-tagged cytoplasmic domains of Ca~V~1.1 (schematically represented in the dashed box). For the II--III loop, dashed line indicates cell surface. **(B)** The GFP-tagged I--II loop of Ca~V~1.2 (indicated in brown) is concentrated at the cell surface both in isolation (dashed box) and when attached to the cytoplasmic domains of Ca~V~1.1 (indicated in blue). Bars, 5 µm.](JGP_201711917_Fig3){#fig3}

[Fig. 4](#fig4){ref-type="fig"} illustrates images of cells coexpressing Stac3-RFP and Ca~V~1.1 cytoplasmic domains (fused to the surface-targeting sequence), obtained after bleaching of RFP within the indicated regions of interest (ROI) in the cell interior. Of the five cytoplasmic domains, Stac3-RFP showed a clear association only with the II--III loop. Similarly, the II--III loop was the only cytoplasmic domain with which Stac1 (Fig. S3) and Stac2 (Fig. S4) showed a clear association. The preferential association between each of the three Stac proteins and the Ca~V~1.1 II--III loop was also evident in the Pearson's coefficients for colocalization ([Fig. 10 A](#fig10){ref-type="fig"}).

![**Stac3 associates specifically with the Ca~V~1.1 II--III loop in tsA201 cells.** Representative images are shown of cells cotransfected with Stac3-RFP and the indicated cytoplasmic domains of Ca~V~1.1, which were targeted to the cell surface by being linked to the GFP-tagged I--II loop of Ca~V~1.2 (compare [Fig. 3](#fig3){ref-type="fig"}). Stac3 associated with the II--III loop of Ca~V~1.1, but not with the other cytoplasmic domains. Pearson's colocalization coefficients are illustrated in [Fig. 10 A](#fig10){ref-type="fig"}. Bars, 5 µm.](JGP_201711917_Fig4){#fig4}

To identify subregions of the Ca~V~1.1 II--III loop important for the Stac protein interaction, we focused on Stac3, because it is the only isoform highly expressed in skeletal muscle. In particular, we coexpressed Stac3-RFP with 69-residue fragments of the II--III loop corresponding to the N- or C-terminal halves (rabbit Ca~V~1.1 residues 662--730 or 731--799, respectively) or the central region (residues 697--765). These fragments are illustrated schematically in [Fig. 5](#fig5){ref-type="fig"}, with orange indicating the residues contained within the critical domain for skeletal-type EC coupling ([@bib20]; [@bib12]; [@bib28]). Stac3 did not associate with the N-terminal fragment of the loop ([Fig. 5 B](#fig5){ref-type="fig"}), but it did associate with the central ([Fig. 5 C](#fig5){ref-type="fig"}) and C-terminal fragments ([Fig. 5 D](#fig5){ref-type="fig"} and [Fig. 10 B](#fig10){ref-type="fig"}). Significantly, the central fragment contained all of the critical domain residues (720--765), and the C-terminal fragment contained most of them (731--765).

![**The interaction between Stac3 and the Ca~V~1.1 II--III loop depends on residues constituting the critical domain. (A)** Schematic representation of the II--III loop of rabbit Ca~V~1.1 (residues 662--799), with orange indicating the critical domain (residues 720--765). **(B--D)** Representative images of tsA201 cells cotransfected with Stac3-RFP and the indicated II--III loop fragments linked to the GFP-tagged I--II loop of Ca~V~1.2. Stac3 interacted only with segments of the II--III loop containing all (C) or most (D) of the critical domain (see [Fig. 10 B](#fig10){ref-type="fig"} for Pearson's colocalization coefficients). Bars, 5 µm.](JGP_201711917_Fig5){#fig5}

As a further test of the importance of the II--III loop critical domain residues, we coexpressed Stac3-RFP in tsA201 cells with polypeptides having the sequence used to replace the II--III loop of Ca~V~1.1 in chimeras that had been previously tested for EC coupling by expression in dysgenic myotubes ([@bib12]; [@bib28]). The II--III loop sequence of these chimeras is illustrated in [Fig. 6 A](#fig6){ref-type="fig"} together with an indication of whether or not that chimera supported skeletal-type EC coupling. As shown in [Fig. 6 (B--E)](#fig6){ref-type="fig"} and [Fig. 10 C](#fig10){ref-type="fig"}, Stac3-RFP interacted with the LCS~46~ and LMS~45~ loops in tsA201 cells, but not with the LC (cardiac) or LM (*Musca domestica*) loops. In some cells, there appeared to be a weak interaction between Stac3-RFP and the LCS~18~ loop ([Fig. 6 F](#fig6){ref-type="fig"}), but this was not apparent in the Pearson's coefficient ([Fig. 10 C](#fig10){ref-type="fig"}).

![**Stac3 interacts in tsA201 cells with chimeric Ca~V~ II--III loops that contain the critical domain. (A)** Summary of II--III loops and their ability, demonstrated in previous work, to mediate skeletal-type EC coupling (ECC) when substituted for the II--III loop of Ca~V~1.1. The designations S, C, or M indicate sequence from Ca~V~1.1 (skeletal), Ca~V~1.2 (cardiac), or Ca~V~ of housefly muscle (*Musca domestica*), respectively. Numbers refer to the first and last residues of Ca~V~1.1 sequence. **(B--F)** Representative images of tsA201 cells cotransfected with Stac3-RFP (red) and the indicated II--III loop constructs linked to the GFP-tagged I--II loop of Ca~V~1.2. Besides the obvious interactions with LCS~46~ (D) and LMS~45~ (E), there may have been a weak interaction with LCS~18~ (F, arrowhead), but this was not consistently observed (see [Fig. 10 C](#fig10){ref-type="fig"}). Bars, 5 µm.](JGP_201711917_Fig6){#fig6}

A pattern of interaction similar to that in tsA201 cells was also observed in dysgenic myotubes cotransfected with Stac3-RFP and GFP-tagged Ca~V~1 chimeras in which the II--III loop was replaced by the sequences illustrated in [Fig. 6 A](#fig6){ref-type="fig"}. In dysgenic myotubes, GFP-Ca~V~1.1 and the GFP-tagged chimeras were all arrayed in discrete foci near the cell surface ([Fig. 7, A--F](#fig7){ref-type="fig"}, left), as expected for targeting to plasma membrane domains forming junctions with the SR ([@bib9]). In agreement with previous work ([@bib23]; [@bib7]), Stac3-RFP coclustered with GFP-Ca~V~1.1 when the two constructs were expressed together in dysgenic myotubes ([Fig. 7 A](#fig7){ref-type="fig"}). This contrasts with the diffuse distribution of Stac3-RFP when it is expressed alone in dysgenic myotubes ([@bib23]; [@bib7]). A similarly diffuse distribution of Stac3-RFP occurred when it was coexpressed with either SkLC ([Fig. 7 B](#fig7){ref-type="fig"}) or SkLM ([Fig. 7 C](#fig7){ref-type="fig"}), chimeras which have Ca~V~1.1 sequence except for a II--III loop replaced by that of either Ca~V~1.2 (SkLC) or that of the calcium channel from housefly muscle (SkLM). However, coclustered red and green puncta were present when Stac3-RFP was coexpressed together with GFP-tagged SkLCS~46~ ([Fig. 7 D](#fig7){ref-type="fig"}) or SkLMS~45~ ([Fig. 7 E](#fig7){ref-type="fig"}), in which the critical domain residues 720--765 or 720--764, respectively, had been inserted into the II--III loops of SkLC or SkLM (compare [Fig. 6 A](#fig6){ref-type="fig"}). A small amount of coclustering was sometimes observed in dysgenic myotubes transfected with Stac3-RFP and SkLCS~18~, in which Ca~V~1.1 residues 725--742 were inserted into SkLC ([Fig. 7 F](#fig7){ref-type="fig"}), but, as for the isolated LCS~18~ loop in tsA201 cells, colocalization was not obvious in the Pearson's coefficients ([Fig. 10 D](#fig10){ref-type="fig"}). Thus, in both tsA201 cells and dysgenic myotubes, the binding of Stac3 depended on the presence, within the II--III loop, of the sequence critical for EC coupling ([@bib12]; [@bib28]).

![**Stac3 interacts in myotubes with full-length Ca~V~1.1 chimeras in which the II--III loops contain the critical domain. (A--F)** Representative, confocal scans near the surface are shown of dysgenic myotubes cotransfected with Stac3-RFP and GFP-tagged, full-length Ca~V~1.1 constructs ("Sk") in which the II--III loop has the sequence indicated to the left of each row of images. Schematic representations of the loop inserts are illustrated in [Fig. 6 A](#fig6){ref-type="fig"}, and Pearson's colocalization coefficients are given in [Fig. 10 D](#fig10){ref-type="fig"}. Bars, 5 µm.](JGP_201711917_Fig7){#fig7}

Having identified an interaction between the II--III loop critical domain and Stac3, we next investigated regions of Stac3 important for this interaction. Because the data illustrated in [Fig. 1](#fig1){ref-type="fig"} indicated that chimeras between Stac3 and Stac1 or Stac2 were unlikely to be informative, we tested varying sized N-terminal deletions of Stac3 for their ability to interact in tsA201 cells with the center segment of the II--III loop that contains the critical domain ([Fig. 8](#fig8){ref-type="fig"}). Stac3 constructs lacking either the first 87 residues ([Fig. 8 B](#fig8){ref-type="fig"}), or the first 146 residues ([Fig. 8 C](#fig8){ref-type="fig"}), were still able to interact with the critical domain-containing segment of the loop, whereas a construct lacking the 302 N-terminal residues was not ([Fig. 8 D](#fig8){ref-type="fig"}). Thus, the first SH3 domain appeared to be required for the binding of Stac3, whereas neither the polyglutamate (pE) nor PKC C1 domains were. As a further test of this latter conclusion, we examined whether the Δ146 Stac3 construct would support functional expression of full-length Ca~V~1.1 in tsA201 cells. As shown in [Fig. 8 E](#fig8){ref-type="fig"}, Δ146 Stac3 did support expression of Ca~V~1.1, although less so than full-length Stac3. The Pearson's colocalization coefficient was also lower for Δ146 Stac3 than for Δ83 Stac3 ([Fig. 10 E](#fig10){ref-type="fig"}) or full-length Stac3 ([Fig. 10 B](#fig10){ref-type="fig"}). Therefore, the PKC C1 domain appears to have contributed to, but was not required for, the interaction between Stac3 and Ca~V~1.1.

![**The polyglutamate and PKC C1 domains of Stac3 are not required for its interaction with the critical domain of the Ca~V~1.1 II--III loop. (A)** Schematic representation (not to scale) and domain architecture of Stac3-RFP and of the GFP-tagged construct containing the middle section of the Ca~V~1.1 II--III loop, including the entire critical domain. **(B--D)** Images of tsA201 cells cotransfected with the indicated Stac3 constructs and the middle section of the II--III loop; for simplicity, the fluorescent and membrane-targeting sequences are not depicted. Stac3 binding occurred for constructs lacking the polyglutamate and PKC C1 domains (B and C), but not for a construct that additionally lacked the first SH3 domain (D). Pearson's colocalization coefficients for these construct combinations are provided in [Fig. 10 E](#fig10){ref-type="fig"}. Bars, 5 µm. **(E)** Comparison of representative peak Ca^2+^ currents (V~test~ = +40 mV, left) and mean peak I--V relationships (mean ± SEM) in tsA201 cells cotransfected with YFP-Ca~V~1.1, β~1a~, and α~2~-δ~1~ either without Stac (green) or with Stac3(Δ146) (purple) or Stac3 (black). Calibrations: 3 pA/pF (vertical), 50 ms (horizontal). The Ca^2+^ currents and peak I--V relationships obtained without Stac, or with Stac3, are replotted from [@bib23].](JGP_201711917_Fig8){#fig8}

Because the function of Ca~V~1.1 in EC coupling requires the presence of Stac3 ([@bib24]; [@bib17]), the question arises as to whether Stac3 is stably associated with Ca~V~1.1 complexes. Previous work analyzed the stability of this interaction with recovery of fluorescence after photobleaching of Stac3-GFP associated with Ca~V~1.1 in myotubes ([@bib7]). At 75 s, the mean recovery, which depends both upon the off rate of bleached Stac3-GFP and the on rate of unbleached Stac3-GFP, was ∼25% ([@bib7]). Here, we have attempted to characterize the off rate directly and over a longer time period. Specifically, dysgenic myotubes that had been cotransfected with GFP-Ca~V~1.1 and Stac3-RFP were permeabilized by a brief exposure to saponin in order to release unbound Stac3 from the cell. [Fig. 9 A](#fig9){ref-type="fig"} illustrates an example of such an experiment with images of a myotube obtained just after (0 min), and at 30 min after, saponin treatment. At 30 min, there was a nearly complete loss of the diffuse red fluorescence, whereas there was much less change in the intensity of the punctate red fluorescence colocalized with GFP-Ca~V~1.1. Mean data, given as the ratio of red-to-green punctate fluorescence, are shown in [Fig. 9 B](#fig9){ref-type="fig"} and indicate that association between Stac3 and Ca~V~1.1 is relatively stable over a time scale of several minutes, with a half-time for dissociation that was on the order of 1 h.

![**Stac3 is stably associated with Ca~V~1.1 in skeletal myotubes. (A)** Confocal images, acquired with identical settings, of the surface of a dysgenic myotube cotransfected with GFP-Ca~V~1.1 and Stac3-RFP immediately (left) and 30 min (right) after saponin permeabilization to release unbound Stac3. Bar, 5 µm. **(B)** Mean ratios ± SEM of red to green fluorescence in colocalized puncta as a function of time after saponin treatment (*n* = 7 from two independent culture preparations from dysgenic mice).](JGP_201711917_Fig9){#fig9}

Discussion {#s12}
==========

Here, we have used fluorescence colocalization and functional measurements to identify amino acid sequences important for the interaction between Stac proteins and Ca~V~1.1. In tsA201 cells, we found that all three Stac isoforms colocalized with Ca~V~1.1 at the surface ([Fig. 1 A](#fig1){ref-type="fig"}), and to a varying extent supported its functional expression as a slowly activating L-type Ca^2+^ channel ([Fig. 1 B](#fig1){ref-type="fig"}). In contrast, Ca~V~1.1 expressed in tsA201 cells without Stac proteins is retained intracellularly ([@bib23]) and fails to produce Ca^2+^ currents ([Fig. 1 B](#fig1){ref-type="fig"}; [@bib23]). Expressed in Stac3-null myotubes, Stac1 and Stac2 were able to restore depolarization-evoked Ca^2+^ transients with peak amplitudes ∼40% of those restored by expression of Stac3 ([Fig. 2](#fig2){ref-type="fig"}). Thus, all three Stac isoforms appear to interact with Ca~V~1.1, supporting its membrane trafficking and its function in EC coupling, with Stac3 clearly being the most effective.

As a tool for identifying Ca~V~1.1 cytoplasmic domains important for interacting with the Stac proteins, we took advantage of the observation that these cytoplasmic domains would associate with the surface of tsA201 cells if they were linked to the GFP-tagged I--II loop of Ca~V~1.2 ([Fig. 3](#fig3){ref-type="fig"}). We found that the II--III loop was the only one of the Ca~V~1.1 cytoplasmic domains that was sufficient for binding Stac3 ([Fig. 4](#fig4){ref-type="fig"}), Stac1 (Fig. S3), or Stac2 (Fig. S4) in this assay. Also with this approach, we found that Stac3 did not interact with a segment of the II--III loop comprising amino acids 662--730, but it did interact with segments containing either residues 697--765 or 731--799 ([Fig. 5](#fig5){ref-type="fig"}). Thus, residues 731--765, which are shared by these latter two segments, likely represent an important binding site for Stac3. Significantly, residues 731--765 constitute the majority of the "critical domain" (amino acids 720--764/5), which was identified on the basis of whether skeletal-type EC coupling could be restored in dysgenic myotubes by the expression of full-length Ca~V~1.1 constructs containing chimeric II--III loops ([@bib20]; [@bib12]; [@bib28]). Thus, we additionally tested the interaction of Stac3 both with the chimeric loops expressed in tsA201 cells without the flanking Ca~V~1.1 sequence ([Fig. 6](#fig6){ref-type="fig"}) and with the full-length Ca~V~1.1 constructs containing the chimeric II--III loops expressed in dysgenic myotubes ([Fig. 7](#fig7){ref-type="fig"}). For both the isolated loops and the full-length chimeras, the colocalization with Stac3 correlated ([Fig. 10](#fig10){ref-type="fig"}) with the ability of the full-length chimeras to mediate skeletal-type Ca^2+^ release, which was shown to be strong for SkCLS~46~ and SkLMS~45~, absent for SkLC and SkLM, and very weak for SkLCS~18~ ([@bib12]; [@bib28]). The rate of release was found to be approximately fivefold lower for SkLCS~18~ than for SkLCS~46~ ([@bib12]). A similar reduction in the binding affinity for Stac3 could account for the lack of colocalization observed in cells coexpressing Stac3 with LCS~18~ ([Fig. 6 F](#fig6){ref-type="fig"}) or SkLCS~18~ ([Fig. 7 F](#fig7){ref-type="fig"}). Thus, our results indicate that the ability of chimeric II--III loops to mediate skeletal-type EC coupling requires that they can bind Stac3.

![**Pearson's coefficients for colocalization of the indicated Ca~V~ and Stac constructs. (A--E)** The constructs were expressed in either tsA201 cells (A--C and E) or dysgenic myotubes (D). The data are presented as mean ± SEM, and for each combination of constructs, both the number of images analyzed and the number of independent transfections are shown on the plots (first and second number, respectively). Representative images are as follows: A, Stac3 ([Fig. 4](#fig4){ref-type="fig"}), Stac1 (Fig. S3), and Stac2 (Fig. S4); B, [Fig. 5](#fig5){ref-type="fig"}; C, [Fig. 6](#fig6){ref-type="fig"}; D, [Fig. 7](#fig7){ref-type="fig"}; and E, [Fig. 8](#fig8){ref-type="fig"} (B--D). \*\*\*, P \< 0.001. Although not indicated on the figure, Stac3 plus either LCS~46~ or LMS~45~ (C) differed from Stac3 plus the Ca~V~1.1 II--III loop (P \< 0.001), and Stac3 plus SkLM (panel D) differed from Stac3 plus LCS~18~ (P \< 0.001) and from Stac3 plus SkLC (P \< 0.008). Note that the same data for Stac3 plus the Ca~V~1.1 II--III loop are plotted in both A and C.](JGP_201711917_Fig10){#fig10}

In addition to investigating the determinants of the Ca~V~1.1 II--III loop that govern its interaction with Stac3, we also performed an analysis of the domains of Stac3 important for this interaction. We found that a Stac3 construct which lacked the polyglutamate and PKC C1 domains still colocalized with a segment of the II--III loop containing residues 731--765 ([Fig. 8 C](#fig8){ref-type="fig"}) and was able to support functional expression of full-length Ca~V~1.1, although to a lesser extent than full-length Stac3 ([Fig. 8 E](#fig8){ref-type="fig"}). A Stac3 construct with a larger N-terminal truncation, which additionally deleted the first of the two SH3 domains, did not appear to interact with this segment of the II--III loop ([Figs. 8 D](#fig8){ref-type="fig"} and [10 E](#fig10){ref-type="fig"}).

[Fig. 11](#fig11){ref-type="fig"} illustrates the sequence of the Ca~V~1.1 II--III loop residues 731--765, which our work indicates are likely to contain a high affinity binding site for Stac3. Previous work had shown that an anti-Ca~V~1.1 monoclonal antibody ([@bib18]) binds to an epitope (amino acids 737--744) that is located within this region ([Fig. 11](#fig11){ref-type="fig"}) and is accessible in fixed and permeabilized muscle cells ([@bib15]). Thus, amino acids 737--744 can likely be excluded as contributing to the binding of Stac3. The upstream amino acids (731--736) also seem unlikely to contribute significantly to Stac3 binding, because this binding was too weak to be detected for the chimeras LCS~18~ ([Fig. 6 F](#fig6){ref-type="fig"}) or SkLCS~18~ ([Fig. 7 F](#fig7){ref-type="fig"}) despite their having Ca~V~1.1 sequence for residues 725--742. Thus, Ca~V~1.1 residues 745--765 may represent the likeliest region for high-affinity binding of Stac3, especially because this region contains adjacent PxxP motifs with a shared central proline ([Fig. 11](#fig11){ref-type="fig"}, green bar), a sequence motif to which SH3 domains have been shown to bind ([@bib2]; [@bib10]; [@bib31]). It should be noted that although the binding of Stac3 to Ca~V~1.1 appears to be necessary for EC coupling, it is clearly not sufficient. For example, skeletal-type EC coupling depends on specific amino acid sequence within the β~1a~ auxiliary subunit of Ca~V~1.1 ([@bib6]; [@bib8]), whereas Stac3 binds to Ca~V~1.1 even when β~1a~ is entirely absent ([@bib23]). Additionally, the critical domain of the Ca~V~1.1 II--III loop appears to have an importance beyond that of the binding of Stac3. In particular, mutating the phenylalanine at position 741 to threonine, which is found at the corresponding position of Ca~V~1.2, causes a ∼75% reduction in EC coupling Ca^2+^ release ([@bib16]), despite the fact that this residue is in a region unlikely to be directly involved in binding Stac3 ([Fig. 11](#fig11){ref-type="fig"}).

![**Localization of a potential Stac3 binding site in the primary structure of Ca~V~1.1.** Alignment is shown of the Ca~V~1.1 II--III loop amino acid residues 731--765 (top) and the corresponding sequence of the Ca~V~1.2 II--III loop (residues 862--896, bottom). Highlighted in yellow is an epitope (residues 737--744) that binds an anti-Ca~V~1.1 monoclonal antibody (mAb; [@bib15]). The bracket (residues 745--765) represents the likeliest region for Stac3 binding containing adjacent PxxP motifs with a shared central proline (green bar, residues 750--756).](JGP_201711917_Fig11){#fig11}

While the work we report on here was under review, another paper appeared in which crystallography and isothermal calorimetry were used to analyze interactions between segments of the Stac proteins and segments of Ca~V~1.1 ([@bib29]). In their experiments, Wong King Yuen et al. found that binding occurred between Ca~V~1.1 residues 728--775 and the region comprising the tandem SH3 domains of all three Stac isoforms, which is consistent with our finding that full-length Stac1, Stac2, and Stac3 all interacted with the Ca~V~1.1 II--III loop. Wong King Yuen et al. also found that the first SH3 domain of Stac3 bound to Ca~V~1.1 residues 747--760, thus providing direct evidence supporting our hypothesis that the PxxPxxP motif (Ca~V~1.1 residues 750--756) represents an important binding determinant for full-length Stac3 ([Fig. 11](#fig11){ref-type="fig"}). Perhaps not surprisingly, however, the effects of mutations on the interactions of the small segments of Ca~V~1.1 and the Stac proteins that were analyzed by Wong King Yuen et al. appear to be much more profound than those of the same mutations harbored in the full-length proteins. For example, when the mutation W329S, which corresponds to a mutation in Stac3 causing the NAM myopathy ([@bib13]), was introduced into the isolated, tandem SH3 domains of Stac2, it eliminated binding to Ca~V~1.1 loop residues 728--775 ([@bib29]). However, full-length Stac3 containing the NAM-causing mutation retains the ability to interact with full-length Ca~V~1.1 in both myotubes and tsA201 cells ([@bib24]; [@bib7]). In particular, mouse Stac3 containing the NAM mutation and expressed in Stac3 null myotubes resulted in a more than 80% reduction in Ca^2+^ release even though membrane expression of Ca~V~1.1 was reduced only ∼20% ([@bib24]). As another example, a triple mutation (I752A, P753A, and R757A) within Ca~V~1.1 residues 728--775 eliminated the interaction between those residues and the tandem SH3 domains of Stac2 ([@bib29]). However, full-length Ca~V~1.1 bearing those same three mutations was still able to support EC coupling Ca^2+^ release in dysgenic myotubes, which was ∼40% of that for wild-type Ca~V~1.1 ([@bib29]).

Our conclusions on Stac interactions diverge in two respects from those of another recent study ([@bib7]). In particular, using different experimental approaches, they concluded that (1) neither Stac1 nor Stac2 interacts with Ca~V~1.1 and (2) the PKC C1 domain is an important determinant of Stac3 binding. In regard to the first of these, they found that neither Stac1 nor Stac2 interacted with coexpressed Ca~V~1.1 in dysgenic myotubes. However, we found that both Stac1 and Stac2 interacted with endogenous Ca~V~1.1 in Stac3-null myotubes ([Fig. 2](#fig2){ref-type="fig"}) and with coexpressed Ca~V~1.1 in tsA201 cells ([Fig. 1](#fig1){ref-type="fig"}). We think a likely explanation for the different conclusions of the two studies is the absence of endogenous Stac3 in the cells that we studied and its presence in the dysgenic myotubes they studied: this endogenous Stac3 could have occluded the binding of exogenous Stac1 or Stac2. In regard to the second divergent conclusion (the role of the PKC C1 domain), Campiglio and Flucher analyzed, in dysgenic myotubes, the interaction of Stac3/Stac2 chimeras coexpressed with Ca~V~1.2 and found that the interaction depended on the presence of the C1 domain of Stac3. We found that in tsA201 cells, a Stac3 construct entirely lacking the PKC C1 domain colocalized with the critical domain of the coexpressed Ca~V~1.1 II--III loop and supported the membrane expression of full-length Ca~V~1.1 ([Fig. 8](#fig8){ref-type="fig"}). Thus, both the constructs (Ca~V~1.2 in their study vs Ca~V~1.1 in ours) and the expression systems were different in the two studies. Additionally, we think it is likely that the binding determinants governing the interactions between the Stac proteins and Ca~V~1.1 differ from those governing the interactions with Ca~V~1.2. For example, Campiglio and Flucher found that in dysgenic myotubes, there was no interaction between Stac1 and Ca~V~1.1 but a significant interaction between Stac1 and Ca~V~1.2.

Interestingly, a PxxPxxP motif, like that in the Ca~V~1.1 II--III loop, is also present in the cardiac (Ca~V~1.2) II--III loop ([Fig. 11](#fig11){ref-type="fig"}), but we found that Stac3 does not bind to the full-length cardiac II--III loop either as an isolated fragment in tsA201 cells ([Fig. 6 B](#fig6){ref-type="fig"}) or when substituted for the II--III loop of Ca~V~1.1 in myotubes ([Fig. 7](#fig7){ref-type="fig"}). This lack of binding could be a consequence of the amino acid differences between Ca~V~1.1 and Ca~V~1.2 within, and flanking, the PxxPxxP motif. Alternatively, the full-length cardiac II--III loop might have a secondary structure that prevents such binding. Nonetheless, it is noteworthy that Stac3 did interact with full-length Ca~V~1.2 in tsA201 cells and alter its inactivation ([@bib23]). Moreover, [@bib29] showed that a Stac3 construct lacking SH3 domains was still able to slow inactivation of Ca~V~1.2 in oocytes. Thus, it appears that neither the II--III loop nor the SH3 domains are involved in the interaction between Stac3 and Ca~V~1.2.

One possibility for the role of Stac3 in EC coupling is that it functions as a link between Ca~V~1.1 and RyR1. Arguing against this possibility is that Stac3 does not appear to bind to RyR1 in the absence of Ca~V~1.1 ([@bib23]). However, it is possible that the interaction with Ca~V~1.1 causes Stac3 to assume a conformation that does interact with RyR1. Conversely, one could imagine that the interaction with Stac3 causes Ca~V~1.1 and its associated β~1a~ subunit to assume an altered conformation that is necessary for interaction with RyR1. In regard to the latter, it would be of obvious value to have a high resolution structure of Ca~V~1.1 assembled with both its auxiliary subunits and Stac3. However, Stac3 appears to have been lost during purification of the Ca~V~1.1 complex that is required for structural analysis by cryo--electron microscopy (e.g., Fig. S1 A of [@bib30]). This may have occurred because the interaction between Stac3 and Ca~V~1.1 is relatively labile. We found that Stac3 dissociated from Ca~V~1.1 clusters with a half-time of ∼1 h in permeabilized myotubes at room temperature ([Fig. 9](#fig9){ref-type="fig"}). However, two factors may have slowed the dissociation in permeabilized myotubes compared with the dissociation that would occur from detergent-solubilized Ca~V~1.1. Specifically, Ca~V~1.1 in muscle cells is localized at junctions between the plasma membrane and SR and is present there at a high, localized concentration. Thus, in permeabilized myotubes, diffusion of unbound Stac3 would have been restricted to two dimensions and rebinding of unbound Stac3 could have occurred to nearby Ca~V~1.1 moieties (that had already lost Stac3). Accordingly, the dissociation of Stac3 from detergent-solubilized Ca~V~1.1 may well be more rapid than we observed for myotubes. Whether or not this is correct, it would seem an important goal for future structural studies to monitor the rate of loss of Stac3 and seek conditions to prevent it.
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